MedPlus Health Services Limited has announced a revised schedule for its board meeting to approve the audited financial results for the fourth quarter and full financial year 2026. The pharmaceutical retail chain issued the updated intimation on May 3, 2026, referencing an earlier communication dated March 28, 2026.

Board Meeting Schedule

The company's board of directors will convene on May 20, 2026, to consider and approve both standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.

Regulatory Compliance and Trading Window

In adherence to SEBI regulations, MedPlus has implemented a trading window closure for designated persons and their immediate relatives. The restriction period spans from April 1, 2026, to May 22, 2026, both days inclusive, extending 48 hours beyond the financial results declaration.

Results Dissemination

Following the board meeting's conclusion, the approved financial results will be submitted to both BSE Limited and National Stock Exchange of India Limited. The company will also publish the results in newspapers as mandated by SEBI LODR Regulations, 2015.

The financial results and related documents will be made available on multiple platforms including the company's official website at www.medplusindia.com , BSE's website at www.bseindia.com , and NSE's website at www.nseindia.com .

Corporate Communication

The revised intimation was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, ensuring proper regulatory compliance and stakeholder communication. This revision demonstrates the company's commitment to transparent disclosure practices and adherence to stock exchange requirements.

MedPlus Health Services Limited has disclosed that its subsidiary Optival Health Solutions Private Limited received a suspension order for a drug license of a store located in Karnataka, according to a regulatory filing submitted on May 1, 2026. The company made this disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Karnataka Drug License Suspension Details

The suspension order was issued by the Assistant Director, Drugs Control Administration, Hubli Circle, Hubli, Karnataka, and was received on April 30, 2026. The action pertains to a store situated at Ganeshpeth Hubli, Karnataka.

Regulatory Compliance Framework

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has provided detailed information about the nature of violations and their financial impact as required under the regulatory framework.

Corporate Communication and Transparency

The regulatory filing was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company has made the documentation available on its official website at www.medplusindia.com , as well as on the stock exchange websites www.bseindia.com and www.nseindia.com .

The company continues to maintain transparency in its regulatory communications and has quantified the potential financial impact of the suspension order at Rs 0.97 lacs in terms of revenue loss during the three-day suspension period.